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Glycomics is a broad and emerging scientific discipline focused on defining the structures and functional
roles of glycans in biological systems. The staggering complexity of the glycome, minimally defined as the
repertoire of glycans expressed in a cell or organism, has resulted in many challenges that must be
overcome; these are being addressed by new advances in mass spectrometry as well as by the expansion
of genetic and cell biology studies. Conversely, identifying the specific glycan recognition determinants of
glycan-binding proteins by employing the new technology of glycan microarrays is providing insights into
how glycans function in recognition and signaling within an organism and with microbes and pathogens.
The promises of a more complete knowledge of glycomes are immense in that glycan modifications of intra-
cellular and extracellular proteins have critical functions in almost all biological pathways.Glycoconjugates (GSLs) exert their biological functions through
complex molecular mechanisms involving both direct glycan
recognition and indirect glycan contributions to conformation
and expression of the GSL. Glycans are directly recognized
by glycan-binding proteins (GBPs) (Figure 1). Such interactions
of glycans with GBPs can promote cell adhesion, cell-matrix
interactions, cellular signaling, glycoprotein folding, and intra-
cellular/extracellular targeting to organelles. In addition, glycans
attached to macromolecules exert control through indirect
mechanisms on glycoprotein conformation, stability, oligomeri-
zation, cell surface resident time, and turnover. Most secreted
and membrane proteins are enzymatically glycosylated on one
or more amino acids (Apweiler et al., 1999; Steentoft et al.,
2013; Van den Steen et al., 1998; Zielinska et al., 2010, 2012),
and virtually all nuclear and DNA binding proteins, cytoplasmic
enzymes involved in metabolic regulation, and some mitochon-
drial proteins have the O-b-N-acetylglucosamine (O-GlcNAc)
modification on Ser/Thr (Bond and Hanover, 2013; Copeland
et al., 2013; Hart et al., 2011; Palaniappan et al., 2013; Yi et al.,
2012). An emerging paradigm of modern glycomics recognizes
that higher animals express a vast repertoire of glycan struc-
tures, which comprise their overall glycomes, and recent
studies are unexpectedly revealing that glycans contribute in
both general and specific ways to almost all biological regulatory
pathways. Thus, as might be predicted, abnormalities in GSL
synthesis or turnover are associated with hundreds of different
human diseases and disorders, including the congenital disor-
ders of glycosylation (CDGs) and dystroglycanopathies, such
as congenital muscular dystrophy (Dennis et al., 2009; Filocamo
and Morrone, 2011; Freeze, 2013; Hennet, 2012; Ju et al., 2013;
Ohtsubo andMarth, 2006). Developing insights into glycan func-
tions and the complexities of glycan structures and conforma-
tions represent both the challenge and promise of glycomics,
the field of science now recognized as focused on glycans,
just as genomics and proteomics are focused on nucleic acids
and proteins, respectively.
This article will focus on some of the major challenges and
promises of the emerging field of glycomics, both structuralChemistry & Bioand functional. Although the term glycomics usually denotes
the chemical aspects of glycobiology, we use this term here as
a shorthand to denote a broad set of research and knowledge
in the chemistry and biology of glycans in terms of structure,
function, biosynthesis, role in biology, and disease, etc. Our
major emphasis will be on human and animal systems, but we
make a point to acknowledge that glycomics and glycoscience
represent broad areas of knowledge and research encom-
passing human and animal biology as well as plant, fungal, and
microbial systems.
Glycan and Glycan Binding Protein Diversity
Glycans occur as both simple and complex structures in thou-
sands of GSLs, which include glycoproteins, proteoglycans,
glycolipids, and free or unconjugated glycans. The factors regu-
lating glycan expression and their molecular and functional roles
have long been a supremely challenging puzzle. Moreover, our
knowledge of the types of glycans and the number of glycan-
amino acid linkages is growing, and the nature of the ‘‘core
structures’’ of glycans in glycoproteins, glycolipids, and glycos-
aminoglycans (GAGs) and glycosylphosphatidylinositol (GPI)-
anchored glycoproteins is expanding at an astonishing rate,
fueled by development of genomics, proteomics, and mass
spectrometry (MS)-based tools (Figure 1). Mammalian glycomes
are built from nine common sugars (Glc, GlcNAc, Gal, GalNAc,
Man, Fuc, GlcA, Xyl, and NeuAc [sialic acid]) with a tenth sugar,
IdoA, being created within presynthesized GAGs. At least nine
amino acids are known to be glycosylated in nature (Asn, Arg,
Ser, Thr, Tyr, Trp, Cys, hydroxylysine, and hydroxyproline)
(Spiro, 2002; Stepper et al., 2011). The surface membrane of
cells may contain over 10 million glycans linked to Asn and
Ser/Thr residues alone, with the concentration of terminal sugars
such as sialic acid approaching 100 mM (Wang et al., 2013).
The spatial and temporal organization and functions of all
these mammalian glycans is largely unclear. While proteomics
is defining protein-protein and protein-nucleic interactions that
are estimated to be in the many hundreds of thousands (Garma
et al., 2012; Venkatesan et al., 2009), with >70% of proteinslogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 1
Figure 1. General Roles of Glycans in Glycoprotein Functions
The general roles of glycans in glycoproteins involve both their direct recognition by glycan-binding proteins (GBPs), and indirect effects of glycans on glyco-
protein interactions, whichmay be dependent on protein-protein, protein-lipid, or even carbohydrate-to-carbohydrate interactions. This includes glycoprotein on
the cell surface, cellular organelles, and in secretions as well as intracellular glycoproteins, e.g., O-GlcNAc glycoprotein. The bottom depicts many of the major
classes of glycan linkages to proteins and lipids, along with the symbol key for representing glycan structures with abbreviations of monosaccharides and other
substituents.
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able protein interaction domain (Liu et al., 2012a; Pawson and
Warner, 2007), glycomics has not yet advanced enough to esti-
mate the number of protein-glycan interactions, i.e., what can
be termed the ‘‘protein-glycan interactome’’. While there is a
growing list of mammalian glycan binding proteins (GBPs) with
defined carbohydrate-binding domains and carbohydrate-bind-
ing modules (see Gupta et al., 2012; Taylor and Drickamer, 2011;
Varki et al., 2009; Vasta and Ahmed, 2009; and http://www.cazy.
org), many new interactions (Tateno, 2010), especially those
involving GAGs, are being discovered and will require further
mechanistic insights to generally define protein motifs governing
glycan recognition. Because the historical term lectin refers to
mainly soluble multivalent proteins capable of agglutinating cells
and lacking enzyme activity, the commonly understood defini-2 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rigtion of lectin would preclude many membrane-bound mono-
valent proteins, antibodies that bind glycans, toxins, microbial
adhesins, enzymes that bind glycans, engineered glycosidases,
and GAG-binding proteins. Thus, the more general term GBPs
encompasses all of these types of proteins, even though the
word lectin appears in many databases. We denote in Figure 1
‘‘Direct Glycan Recognition,’’ where a glycan determinant is
directly bound by a GBP, and ‘‘Indirect Glycan Effects’’ that
range from glycan-glycan interactions (Handa and Hakomori,
2012), protein solubility, protection from proteolysis and immune
surveillance to affecting protein conformation and associations
of GSLs in the plasma membrane, for example. Given the
growing evidence that the human and individual animal glyco-
mes contain thousands of glycan species (Cummings, 2009) as
well as evidence for hundreds of different GBPs encoded inhts reserved
Figure 2. Glycan-Related Genes
Compilation of data from several databases
identifies glycosylation-related human and mouse
genes (glycogenes). Modified and updated from
Nairn et al. (2008).
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Zhang, 2010) (Figure 2), it is possible that the number of protein-
glycan interactions may approach that of protein-protein and
protein-nucleic interactions, especially considering that many
of the GBPs in animals interact with glycans derived from the mi-
crobiome aswell as those expressed by themyriad of pathogens
that infect these animals (van den Berg et al., 2012).
Studies on glycan structures and functions are complicated by
the facts that most glycans in human and animal tissues remain
poorly defined structurally, expression is typically cell type-spe-
cific and developmentally- and differentiation-dependent, little is
known about the factors governing glycosylation on specific pro-
teins and at specific sites, and virtually nothing is known about
the overall architecture and topology of glycan expression on
and within cells. However, recent developments in this field
have been spurred, not only by the important biological functions
of glycans being revealed through genetic studies, but also
through breakthroughs in technologies involving MS as well as
glycan microarray analyses that demonstrate the wide distribu-
tion and binding specificities of GBPs. Together, the genetic in-
formation and GBP information are being combined to promote
a functional understanding of glycans, which has been termed
‘‘functional glycomics’’. Although the current picture presented
here underscores the tremendous challenges in the field, the
landscape of glycoscience is rapidly changing, and the field
is at the threshold of significant breakthroughs that will rever-
berate throughout biology. Such discoveries are highlighting
the position of glycans as one of the four major classes of life’s
macromolecules, on the center stage of modern biomedical
and chemical research (Marth, 2008).
Glycan Microarrays and Glycan Determinants
Protein-glycan interactions were historically studied using
the hapten inhibition approach in laborious precipitation orChemistry & Biology 21, January 16, 20hemagglutination-type assays. Such ap-
proaches were far from high throughput,
lacked sensitivity, and required large
quantities of valuable glycans, thus
limiting binding studies to monosac-
charides and short oligosaccharides or
poorly defined complex glycoconjugates
isolated from natural sources. This
approach led to the prior paradigm that
GBPs have relatively low affinity and
lack strong specificity. However, within
the last decade and beginning with the
introduction of ELISA-type assays in the
late 1990s, studies have used microarray
technologies in which large libraries of
complex glycans are immobilized on sur-
faces, akin to nucleic acid arrays. These
glycan microarrays have helped to revo-lutionize the field of glycobiology and provided the ability to inter-
rogate putative binding specificities of GBPs by researchers
in a wide spectrum of biomedical and basic sciences in a fashion
unimaginable a decade ago. Glycan microarrays can be interro-
gated by indirect or direct fluorescence-based techniques to
identify specific binding of glycans by lectins, antibodies, toxins,
viruses, etc. (Figure 3).
The Consortium for Functional Glycomics (CFG), developed
through a large scale collaborative project from the National
Institutes of Health (NIH)/National Institute of General Medical
Sciences, made available a printed glycan microarray (Blixt
et al., 2004) that continues to be available to the research
community (Rillahan and Paulson, 2011; Smith and Cummings,
2013), and data generated are posted and publicly available
(http://www.functionalglycomics.org/). Over 15,000 glycan
microarrays or slides from the CFG have been used over
the past decade by researchers in 3,000 array experiments
with >1,000 types of samples containing GBPs, including human
and animal sera as well as intact eukaryotic and prokaryotic
cells. The database of the CFG is the world’s largest catalog of
protein-glycan interactions. The work of the CFG is complemen-
tary to those of many other laboratories worldwide involved in
developing glycan microarrays and probing them with a variety
of GBPs and other reagents (Chevolot, 2012; de Paz and See-
berger, 2012; Liu et al., 2009; Park et al., 2013). Smaller libraries
of glycans have also been usefully explored for binding to GBPs
using solution-based approaches (Arata et al., 2001; Chang
et al., 2011; Duverger et al., 2010; Gutie´rrez Gallego et al.,
2004; Takeda et al., 2013). However, a need in the future is for
all users of glycan microarrays to deposit their data in publicly-
available databases for curation and cataloging in relation to
the larger effort to define the protein-glycan interactome.
The results of glycan microarray studies using different plat-
forms and different types of glycans are revealing that many14 ª2014 Elsevier Ltd All rights reserved 3
Figure 3. Methods to Explore Glycan Recognition—Glycan Microarrays
To explore protein-glycan interactions, one major technology in the field is glycan microarrays. In such an approach, individual glycans from natural sources or
chemo/enzymatic syntheses are modified to allow their automated printing and attachment, either covalently or noncovalently, to a slide-type surface in defined
positions, akin to a gene array. The glycan microarray can be interrogated with GBPs or other reagents or even cells and viruses to identify those glycan ‘‘spots’’
that are recognized, which can be visualized by either direct or indirect fluorescent tagging. The spot pattern on the image, which should also incorporate
replicates of each glycan, can be averaged to generate a histogram. In the example shown, the results indicate that that the GBPs in question bound strongly
to one glycan, less strongly to another glycan, and did not bind appreciably to any other glycan. Such microarrays can also be prepared from glycolipids,
glycopeptides, whole glycoproteins, or polysaccharides of animal, plant, or microbial origins.
Chemistry & Biology
ReviewGBPs, including antibodies, display relatively high affinity inter-
actions with complex glycans, often involving 3–7 monosaccha-
ride residues, which includes branched structures or saccharide
modifications such as sulfation or phosphorylation. Researchers
are moving away from a focus on the minimal determinants that
might inhibit a lectin binding to a single glycan, such asmillimolar
concentrations of monosaccharides or simple glycans, to the
concept of the biological and physiological interactions between
relevant naturally occurring GBPs and relatively complex glycan
structures (Wang et al., 2013). The concept of ‘‘glycan determi-
nants’’ (Cummings, 2009), which are the ‘‘minimal’’ glycan struc-
tures that confer the ‘‘maximum’’ glycan binding affinity, may be
thought of as akin to antibody epitopes or glycotopes (Cao et al.,
1996). This concept helps us understand the contributions of
individual glycan features and biosynthetic pathways to glycan
recognition. However, such array studies naturally raise ques-4 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rigtions as to their physiological relevance, and there are concerns
of glycan ‘‘presentation’’ onmicroarrays and the degree to which
this presentation is biologically relevant to their presentation on
cell surfaces or native GSLs (Park et al., 2013).
It should be self evident that binding or lack of binding of GBPs
to glycans on glycan microarrays or other surfaces does not
directly provide evidence of functionally significant interactions,
but such results can provide hypotheses to be tested regarding
particular glycan functions. In many cases, ligands predicted by
glycanmicroarray analyses have been shown to have physiolog-
ical relevance, whereas, in some cases, the connection is less
clear. Examples of the former are results of virus binding, such
as influenza viruses and noroviruses, which bind in microarrays
and in vivo to sialylated (Blixt et al., 2004; Stevens et al., 2006;
Walther et al., 2013) and blood groupH-type glycans (Lindesmith
et al., 2003; Shang et al., 2013), respectively. Another example ofhts reserved
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functions are studies on CD22 (Siglec-2), which was shown to
bind glycans with NeuAca2-6-linked sialic acid on cells in vitro
(Macauley et al., 2013; Powell et al., 1993; Sgroi et al., 1993),
in solution studies (Powell and Varki, 1994), in glycan microar-
rays (Campanero-Rhodes et al., 2006; Tateno et al., 2008), and
in mice (Hennet et al., 1998). A possible example of discordance
between glycan microarray data and physiological ligands in-
volves recent studies on Siglec-F in mice. Both human Siglec-8
and its murine homolog Siglec-F preferentially recognize
the same sialylated glycan 6’-sulfo-sialyl Lewis X (6’su-SLex -
NeuAca2-3[6-SO3]Galb1-4[Fuca1-3]GlcNAc-R), evidence in
part based on binding to immobilized arrayed glycans (Bochner
et al., 2005; Kiwamoto et al., 2013; Tateno et al., 2005). This Si-
glec is expressed in eosinophils, and its binding to 6’su-SLex has
been proposed to be important in mitigating allergic eosino-
philic airway inflammation. Studies in vivo indicate, however,
that although St3gal3 mutants lacking the sialyltransferase had
diminished Siglec-F binding and more intense allergic eosino-
philic airway inflammation (Kiwamoto et al., 2014), deletion of
the sulfotransferases capable of generating 6-sulfated galac-
tose, as determined by glycomic analysis, did not appreciably
affect Siglec-F binding in a mouse model (Patnode et al.,
2013). Thus, in all cases where it is experimentally feasible, it
is critical to link the results of glycan microarray analyses for
GBP glycan determinants with physiological evidence for such
glycan determinants being functionally important. It is also
important to note that current glycan microarrays lack the full
presentation of structures found in the human and animal glyco-
mes. Thus, many potentially important glycans and glycan deter-
minants are lacking, and lack of binding of a protein to a glycan
microarray may simply indicate that the relevant glycan ligand is
missing.
Although the number of structurally different glycans in the hu-
man glycome is presently unknown, it is likely to be many tens of
thousands. The repertoire of glycan determinants in the human
glycome, however, is estimable. An approach to this problem
is to conceptually assemble partial determinants or segments
of glycan structures with each other in biochemically allowed
and defined ways based on known biosynthetic pathways and
glycan structures (Cummings, 2009; Rademacher and Paulson,
2012; Werz et al., 2007). Such a combinatorial approach permits
calculations as to howmany such determinants might exist in N-
and O-glycans and glycolipids, as well as GAGs. An illustration
using partial determinants shows that that there are possibly
many thousands of glycan determinants (Figure 4). Few of these
glycan determinants are currently available on available microar-
rays (the current CFG glycan microarray has 611 different
glycans); thus, there is a tremendous need for chemical and
enzymatic syntheses of thousands of compounds. Fortunately,
the NIH has funded the development of small libraries of
synthetic glycans as a first step in expanding the availability of
glycans to the research community (http://sbir.cancer.gov/
funding/contracts/fy2013_09.asp). Coupled with advances in
asymmetrical synthesis of glycans (Wang et al., 2013), these ef-
forts should be encouraged, because a large number of glycans
are obviously needed for structural and functional studies and as
standards for nuclear magnetic resonance (NMR) and MS ana-
lyses. In any case, the need for an increased number of syntheticChemistry & Bioglycans in sufficient quantities to impact glycan analysis and
functional studies far exceeds their availability.
Milk and Glycolipid ‘‘Metaglycomes’’ as a Paradigm for
Glycomics
Although the human glycome certainly represents a challenge in
terms of defining all its structures, themetaglycomes of cells and
tissues may be amenable to total analysis. We use the term
‘‘metaglycome’’ to denote a constituent glycome of a specific
cell or tissue as well as a type or family of glycoconjugates sum-
ming up all of the human metaglycomes would then define the
human glycome. In fact, targeting specific metaglycomes and
providing their repertoire of glycans would likely constitute a
milestone toward the direction of eventually defining the human
glycome. Two such metaglycomes that would be amenable
to such analyses are the soluble human milk oligosaccharides
or glycans and human glycosphingolipids GSLs. The sizes of
both of these metaglycomes have already been estimated,
with the HMO comprising several hundred glycans (Bode,
2012; Urashima et al., 2011), and the human GSL metagly-
come comprising at least 500 different glycosylated neutral
and acid species, based on the LIPID MAPS database (http://
www.lipidmaps.org/), without consideration of the aglycone
lipid constituents. Importantly, technologies appear to be in
place to allow quantitative and qualitative descriptions of both
the free glycans in human milk (Bao et al., 2013; Ninonuevo
et al., 2006) and releasable glycans from GSL glycomes (Fujitani
et al., 2011). Interestingly, both of these metaglycomes have
terminal Glc as the nonreducing sugar (lactose-type glycans
in milk and lactosylceramide-type glycans in GSLs), so
technologies for defining the glycans may be overlapping and
synergistic. Recent technological advances indicate that GSL
metaglycomes may be approached using intact lipids, which
maintains information regarding aglycone dynamics as well
(Boccuto et al., 2014).
A common conundrum for the glycomics field is: how will re-
searchers know that they have fully defined a metaglycome?
The evidence that a metaglycome is largely, if not fully, defined
would be based on the pace of discovery of new glycan species
within such metaglycomes in the future; thus, at some point in
time, the pace of discovery would lessen to the point that one
could estimate that > 95%of the glycans below a certain reason-
able size limit, e.g., 5,000 Da, had been described for that meta-
glycome. The definitive description of a metaglycome to that
level, with calculated and statistical reasoning, would go far in
assisting the development of technologies and bioinformatic
approaches that will provide researchers with their first break-
through paradigm in defining at least two specific component
metaglycomes of the human glycome. A clear challenge to the
field of glycomics is that if we cannot fully define the HMO and
GSL metaglycomes, how can we possibly imagine defining the
glycoprotein-derived metaglycomes, which are clearly much
more complex?
The complexity of glycomes parallels the technical difficulties
in analyses as well as the number of glycan determinants that
might exist (Figure 5). Thus, one could imagine that GAGs, with
their multitude of potential disaccharide repeating units, would
represent the most complex set of glycans in the human gly-
come, whereas GPI-anchors and human milk oligosaccharideslogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 5
Figure 4. Illustration of the Complexity of Glycan Determinants
GBPs often recognize 2–6 linear or branched monosaccharides with additional modifications, such as phosphorylation, sulfation, O-acetylation, etc. Such
recognition can be termed a glycan determinant, which is the minimal glycan structure that confers maximumbinding. These glycan determinants can be thought
of as being assembled from partial determinants, which, in the example shown, are modified galactose, modified Gal-GlcNAc, and modified GlcNAc-Man. With
the partial determinants shown, which are 6, 9, and 3 in number, respectively, it is possible to assemble these into 162 different glycan determinants. Also shown
are two of these as Determinant 1 and 2, which are differently recognized by aGBP orGRM. If one considers all such known partial determinants in human glycans
defined to date, it is possible to predict that there are over 5,000 glycan determinants; if the GAG sequences are also included up to pentasaccharides, then there
are an additional 10,000 or so. It is likely that this is an underestimate for the total theoretical glycan determinants, because it is likely that other partial
determinants will be identified in the future. In addition, it is possible that, in a single branched or linear glycan, the one set of glycan determinants may attenuate
the recognition of the same or a different glycan determinant on the same molecule.
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studies in glycomics should focus to some degree on the meta-
glycomes that are most definable, and functional glycomics can
then define the recognition of those glycans by GBPs or the spe-
cific roles of those glycans in human physiology and disease.
Such a strategy could lead to the identification of the protein-
glycan interactome for that particular metaglycome.
In the absence of either knowing all the structures in the human
glycome or having all glycan determinants available as syn-
thetic compounds, it is possible to use a ‘‘shotgun glycomics’’
approach, prior to definitive structural characterization, to obtain
all the cellular glycans and use fractionated glycan species for6 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rigfunctional studies on glycan microarrays and other surfaces.
Such a shotgun approach has been successful in many cases
for preparing total GSL-derived glycan libraries and other types
of natural glycans (Liu et al., 2012b; Song et al., 2011; van Diepen
et al., 2012). The combined approach of general glycomics, the
release of all the glycans from endogenous GSLs and subse-
quent structural analysis, with functional glycomics, where indi-
vidual purified glycans species are probed for their functional
recognition by GBPs (Smith and Cummings, 2013), is highly
likely to make significant strides to unravel both the mysteries
about the glycan structures that make up the glycome and their
recognition by endogenous and pathogen-derived GBPs.hts reserved
Figure 5. Relationships among Glycome Complexity, Number of
Glycan Determinants, and Difficulty of Glycomic Analysis
The different classes of glycans, from the GPI glycans within GPI-anchored
glycoproteins to the GAGs, represent different levels of complexity and
number and diversity of glycan determinants. Of course, with the complexity
and increased numbers of determinants, the analytical difficulties expand
tremendously. Thus, a great challenge of glycomic technologies is to discover
find better methods of preparing and analyzing glycans to overcome the
challenges of their complexities.
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Over a hundred different plant lectins and a few from inverte-
brates have been identified, and many, such as Concanavalin
A (Jack bean) and Helix pomatia agglutinin (snail), have been uti-
lized successfully to study glycan expression and function. The
use of glycan microarrays has allowed the binding determinants
of a large number of lectins to be explored, thereby greatly
facilitating their utility in testing hypotheses regarding glycan
function. The repertoire of human and mouse glycan structures
recognized by the plant lectins commonly available is quite
limited, however, and often a single lectin binds to multiple
glycan structures carrying minimal glycan determinants. In addi-
tion, analysis of the binding specificities of commercial plant
lectins by the glycan microarray screening of the CFG has
demonstrated remarkable inconsistencies among commercial
preparations of the same lectin, including variable binding
affinities and even inactive preparations. The field of glycomics
is at a point where more reliable and better-defined reagents
that recognize a breadth of glycan structures are required. More-
over, if investigators encompassing the breadth of biomedical
research had these types of reliable reagents available, a signif-
icant increase in our knowledge of glycan function would, no
doubt, occur. The time is right to consider developing an exten-
sive library of glycan recognition molecules (GRM) with specific-
ities and determinants defined by binding to expansive glycan
microarrays. These reagents, if made available to researchers
with diverse health-related interests, would greatly accelerate
the pace of glycan function discovery in physiology and disease.
These reagents could also provide a direct means to target spe-
cific glycans for potential therapeutic and diagnostic applica-
tions. There are novel platform technologies in the early stages
of development that can generate and select for molecules
that recognize and bind specific glycan structures. TheseChemistry & Bioinclude antibodies or antibody-like proteins as well as nonpro-
tein molecules such as nucleic acid aptamers (Li et al., 2008)
and synthetic lectins (Ke et al., 2012). Because some of these
GRMs are not proteins, here we refer to this class as GRM,
instead of GBP. Potential technologies for generation and selec-
tion of antibodies with specificity for specific glycan epitopes
include the engineering of glycans, glycopeptides, and novel ad-
juvants to elicit high-affinity IgG (Lakshminarayanan et al., 2012),
yeast display of scFv antibodies (Zhao et al., 2011), and lamprey
antibodies (Yu et al., 2012). In addition, the elucidation of glycan
binding specificities of viruses, bacteria, and both plant and
animal lectins (using glycan microarrays) as well as the structural
knowledge of these GBPs plus many glycan-recognizing en-
zymes provide a structural basis of glycan bindingmotifs. Knowl-
edge of these motifs, coupled with detailed structural studies of
glycan binding domains by crystallography and NMR spectros-
copy, as well as molecular simulations of glycan-protein inter-
actions, have led to an expanding understanding of how to
engineer glycan recognition determinants (e.g., Feinberg et al.,
2013; Ford et al., 2003; Mercer et al., 2013). This knowledge
could be exploited to assist the design and selection of GRM
with glycan binding determinants and specificities of interest.
The prospect for the availability of libraries of GRM is some-
what analogous to the availability of antibodies directed against
specific phospho-peptides for studies of cell signaling path-
ways and the development of restriction enzymes for molecular
biology. Availability of these sequence-specific reagents has
allowed the investigation of signaling pathways and nucleic
acids by nonexpert investigators with diverse interests. Like-
wise, GRM would assist in testing for changes of glycan epitope
expression and would also provide new tools for assessing func-
tions by potentially blocking or crosslinking target glycans. Pro-
duction of GRMwill involve muchmore complex challenges than
for peptide or phospho-peptide-specific antibodies or restriction
enzyme identification because of the diversity of glycan struc-
tures, and their precise binding determinants must be deter-
mined using glycan microarrays and other approaches, akin to
what was done for the cluster of differentiation in immunology
(http://www.sciencegateway.org/resources/prow/). Despite the
obvious challenges, the availability of defined GRMs to pursue
specific biological questions will likely be transformative.
Glycomic Analyses of Various Types of Glycoconjugates
and Their Recognition by GBP
A clear challenge of glycomics is the complexity of analytical
methods for individual classes of glycans, as discussed here.
Each class requires different methods of extraction or glycan
release, often different methods of analysis, or combinations of
methods, such as high-performance liquid chromatography
(HPLC), MS, NMR, etc. (Figure 6). Nevertheless, although com-
plex, each of these methods has been adapted to provide
deep insights into glycan structure for that particular glycan
class. An all-encompassing method of glycoprotein analysis
at the top-down level would be ideal, and coupled with
the bottom-up approaches (Hanisch, 2012; Nicolardi et al.,
2013), would help to define the relationships of glycans to their
protein and lipid carriers and their relative abundance to each
other. Moreover, analytical approaches capable of probing the
glycomes of living cells, as through biorthogonal methodslogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 7
Figure 6. General Glycomic Strategies
The general strategies for glycomic analyses typically involve isolating or generating free glycans from glycoproteins/proteoglycans and glycolipids. The obtained
mixture of glycans can then be derivatized and directly analyzed by MS or derivatized, separated by HPLC and other approaches, and further analyzed by MS or
NMR. In shotgun glycomics for functional studies, the released glycans after separation can be printed to generate glycan microarrays. For site-specific
glycosylation and identification of protein carriers, glycopeptides can be generated by proteolysis and then analyzed directly before or after glycan removal.
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approaches, would provide breakthroughs into the dynamical
aspects of glycomes in living tissues.
Glycosphingolipids
The majority of the current methodologies for preparing glycans
beginning with cell/tissue extraction are depicted in Figure 6.
Obviously, the challenges for structural determination for the gly-
cans on these diverse classes of GSLs are formidable and call for
more facile technologies with automated annotation. Beginning
the discussion with GSLs, sophisticated analytical platforms
have been developed for their separation and resolution, ranging
from thin-layer chromatography to HPLC (Levery, 2005; Suzuki
et al., 2011). In many cases, the glycan moieties are released
and analyzed separately from the ceramide aglycone, although
the accuracy and speed of current mass spectrometers are
facilitating the analysis of intact GSLs. In either case, MS is
then used to characterize the glycans; multi-stage MS (MSn)
analyses obviously yield more-definitive structural assignments.
Two new methodologies rely on either prior permethylation of
the GSLs after initial extraction, allowing liquid chromatog-
raphy-tandem mass spectrometry (LC-MS)n, or direct infusion
of MSn to resolve each permethylated species to quantify individ-8 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rigual GSL with detailed structural information of both glycan and
lipid moieties of each species (Boccuto et al., 2014) or the use
of MALDI-quadrupole ion trap-TOF in negative ion mode (Ito
et al., 2009). Neural tissue contains the most complex GSLs,
but they are expressed and have various functions in all cells.
Some of these functions serve to regulate outside-in signaling
pathways, particularly by modulating cell surface receptor asso-
ciation with other membrane proteins that can, in turn, affect
efficacy of signaling (Figure 1). For example, the signaling of the
insulin receptor can be strongly attenuated when it is in associa-
tion with GM3; the levels of this ganglioside increase in response
to inflammatorycytokinessuchas tumornecrosis factor-a, result-
ing in a loss of insulin receptor function (Inokuchi, 2010;
Kabayama et al., 2007). There are also many examples of direct
glycan recognition (Figure 1) between GBP and GSL, as well,
such as the binding of myelin-associated glycoprotein (Siglec 4)
to GD1a and GT1b. Moreover, pathogens such as Vibrio cholera,
Shigella dysenteriae, andClostridium tetani all secrete toxins that
bindspecificGSLsoncell surfaces.Adiscussionofmicrobial pro-
teins that recognize cell surface GSL and other types of glycans
can be found in Essentials of Glycobiology,Chapter 28 and other
sources (Day et al., 2012; Karlsson, 1989; Topin et al., 2013).hts reserved
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by GBP
Asparagine-linked glycans (N-glycans) have been extensively
studied in terms of their structures and precise functions (More-
men et al., 2012). Most of the endogenous GBPs for humans
and mice whose ligand specificities are known bind to N-
glycans (see http://www.imperial.ac.uk/research/animallectins/
ctld/lectins.html and http://www.functionalglycomics.org/
glycomics/publicdata/primaryscreen.jsp. Because of their larger
size and extensive branching, the N-glycans are the most
complicated non-GAG structures to analyze, because, for
example, a tetraantennary glycan can have heterogeneous
branches that are even isobaric. These individual branches
are difficult to resolve using any number of separation and
MS-based platforms of analysis, but progress is being made
(Yu et al., 2013a). The analysis of N-glycans, whereby they are
released from glycoproteins or glycopeptides using PNGase
F or chemical means such as hydrazinolysis, is depicted in
Figure 6. Recombinant PNGase F releases all N-glycans found
in humans and mice, leaving an Asp acid rather than Asn at the
site of attachment to the protein and producing free glycan
with an intact reducing terminus. Several methods have been
developed to use this enzyme to incorporate 18O into the Asp
where a glycan was attached (Ku¨ster and Mann, 1999). Sub-
sequent proteolysis can then produce peptides, some of which
have incorporated 18O, that allow the identification of the specific
peptides that had an N-glycan attached. Large scale analysis of
N-glycans in tissues and serum has been performed by MSn
using different techniques to enrich for this class of structures.
One study utilized four mouse tissues and serum to identify
6,367 N-glycosylation sites on 2,352 proteins; over 99% of these
contained the canonical Asn-X-Ser/Thr motif (where X is not
Pro); however, a small fraction of these sites actually utilized
the Asn-X-Cys motif (Zielinska et al., 2010).
Identification of released N-glycan structures has been pur-
sued by many investigators and methods (reviewed in Han and
Costello, 2013; North et al., 2009). It is useful to distinguish be-
tween methods that are facile for the discovery of novel glycans
or discriminate between isobaric structures, in contrast to those
that are optimal for detecting and quantifying structures in a
more routine manner with potential for high-throughput analysis.
One of the classic techniques used mainly for quantifying
mixtures of N-glycans, after release from its protein or peptide,
is tagging of the reducing termini of glycans with a fluorescent
compound and separating the various species via HPLC or
capillary electrophoresis (Doherty et al., 2012). This methodol-
ogy has been very successfully scaled to high-throughput and
automated analysis, allowing large populations of samples to
be analyzed. Although, because it is based mainly on retention
time differences determined for standards whose structures
have been demonstrated by a variety of means, glycans with
unusual or unexpected structures may not be resolved. Glycosi-
dase digestions can often aid in structural assignment. A recent
study profiling the N-linked structures detected on the major
serum glycoproteins of a large population, coupled with a
genome-wide association study of the genomes of those
whose sera were analyzed, suggested that the transcription fac-
tor HNF1a is involved in regulating fucosylation of N-glycans on
serum glycoproteins (Thanabalasingham et al., 2013). Fluores-Chemistry & Biocent tagging of glycans still yields one of the lowest thresholds
of glycan detection compared to other methods, including
various types of MS.
Analyses of released N-glycans by mass spectrometric
methods range from simple MALDI-TOF to those that employ
permethylation, followed by purification and MSn techniques.
Permethylation assists in extraction of glycans from peptides
and other contaminants, neutralizes negative charges, amplifies
differences in masses between somewhat similar species, and is
able to decrease variability between various molecular ions to be
detected by the mass spectrometer. In addition, fragmentation
of permethylated glycans produces scars at previous sites of
glycosidic linkage, providing additional structural information.
Obviously, because of themany isobaric structures found inmix-
tures of N-glycans, definitive characterization requires fragmen-
tation and extensive analysis (see minimum information required
for a glycomics experiment [MIRAGE] below). Quantitation can
be done by the total ion mapping method (Aoki et al., 2007),
but other methods, also based on those developed for prote-
omics, have been developed (North et al., 2009; Orlando,
2010). Attempts are being made to automate some of these
types of analyses, which will significantly accelerate throughput
and move glycan analysis from a specialty to a more common
practice.
N-glycans are essential in the quality control of glycoprotein
folding and the intracellular trafficking of glycoproteins (Aebi,
2013; Braakman and Bulleid, 2011). Many of the endogenous
GBP discovered thus far in humans and mice bind to N-glycans
and function in these pathways. The first description of an animal
GBP, (Figure 1 Type I), the ‘‘Ashwell-Morell receptor,’’ also
termed the hepatic asialoglycoprotein receptor, and founding
member of the C-type lectins, is expressed on hepatocytes
and binds to N-glycans on glycoproteins when they have termi-
nal galactose due to exposure to neuraminidase (Hudgin et al.,
1974). Recent studies have demonstrated that this receptor
shows selectivity to ligands that are exposed on desialylated
glycoproteins involved in prothrombosis induced by bacterial
infection (Grewal et al., 2008). N-glycans also have prominent
functions in Type II, indirect glycan effects in regulating glyco-
protein function, regulation of glucose transporter (Ohtsubo
et al., 2005), receptor half-life on the cell surface (Partridge
et al., 2004), and modulation of the effector functions of the Fc
moiety of immunoglobulin G (IgG). Evidence has been presented
indicating that intravenous Ig is therapeutically anti-inflammatory
(Nimmerjahn and Ravetch, 2008) and that a2-6-linked sialic acid
on N-glycans of IgG are immunosuppressive (Anthony et al.,
2008a; Kaneko et al., 2006) and may bind to DC-SIGN and
murine SIGN-R1 (Anthony et al., 2008b; Schwab et al., 2012)
to signal the downstream expression of immunosuppressive
cytokines and receptors, but more recent studies question
some of these prior interpretations (Yu et al., 2013b).
O-glycan Analysis and Recognition by GBP
O-glycans in humans and mice range from the shockingly ubiq-
uitous O-GlcNAc modification of Ser/Thr found in intracellular
and nuclear proteins (thereby qualifying them to be considered
as glycoproteins) (Copeland et al., 2013), to the large family
of proteins that contain Ser/Thr-O-GalNAc that is normally
extended by other glycans and glycan modifications. Almost
all proteins with a predicted signal sequence are also predictedlogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 9
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et al., 2013). Other O-linked glycan modifications include O-Fuc,
O-Glc, and O-Man; in fact, one-third of O-linked protein modifi-
cations in rat brain have been shown to be O-Man (Chai et al.,
1999). Compared to N-glycans, only a few GBPs have thus far
been shown to bind O-glycans, suggesting that there are many
more of these GBPs to be discovered. The most prominent of
these GBPs is P-selectin, which is expressed on activated endo-
thelia and functions in the first step of the inflammatory response
involving cell adhesion (Wilkins et al., 1995). Of particular note is
the recent study showing a unique O-Man-linked glycan with an
unusual repeating polymer of xylose and glucuronate that serves
as the ligand for laminin found in basement membranes (Inamori
et al., 2013; Yoshida-Moriguchi et al., 2010). This laminin-glycan
interaction is responsible for adhesion between many cell types,
including muscle and nerve, epithelia, and basal lamina and
is affected in cancer cells as well as in several of the CDGs
(Freeze, 2013) that affect muscle and nerve function (e.g.,
Yang et al., 2013). This result also demonstrates that novel
glycan structures are still being discovered and that O-glycans
can clearly function as ligands for endogenous GBP. The cad-
herin family of proteins has also recently been shown to express
significant levels of O-Man-containing glycans (Vester-Christen-
sen et al., 2013).
Because of the lack of an equivalent of a pan-specific PNGase
for O-glycans, structures attached to Ser/Thr residues are typi-
cally released by b-elimination via mild base/borohydride or
other basic reagents. After release, their separation and quanti-
tation are accomplished by methods similar to N-glycans. There
are examples of proteins that have over 1,000 O-GalNAc gly-
cans, whereas others have only a single O-linked GalNAc modi-
fication. The diversity of O-GalNAc glycans in a single mucin is
staggering when modifications such as sulfation are taken into
account; for example, human Muc5ac from patients with cystic
fibrosis contains over 260 distinct glycan structures, determined
by release, fluorescent tagging, HPLC separation, and MS
analysis (Xia et al., 2005). Glycosylation of mucins is often cell-
and tissue-specific and altered in disease states (Larsson
et al., 2011). The factors that determine selectivity of particular
O-GalNAc modifications are only beginning to be understood
(Steentoft et al., 2013). The generation of technologies to
generate cultured cells that lack particular glycosyltransferases
represents a significant step toward understanding the mecha-
nisms that regulate this diversity of glycan structures. Applica-
tion of MS methods that select specific molecular ions that,
when fragmented, serve as signatures for particular O-glycan
structures, usually employing tandem MS, can quantify O-gly-
cans in a mixture released from an isolated glycoprotein, serum
or cell-derived glycoproteins. This method of selected reaction
monitoring and consecutive reaction monitoring or their variants
offers the possibility of automation and relatively high throughput
of O-glycan analysis and can be used to identify specific glyco-
protein glycoforms (e.g., Sanda et al., 2013; Zhang et al., 2012).
GAG Analysis and Recognition by GBP
Analysis of GAGs relies mainly on characterization of disaccha-
rides after enzymatic cleavage and further analysis using tan-
dem MS sequencing (reviewed in Zaia, 2013). Clearly, GBPs
bind GAGs; the example of antithrombin III binding to heparin
is perhaps the most prominent, although these GAG-binding10 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rGBPs are often not classified as lectins, because they lack the
signature fold that has been identified for various lectin families.
Nonetheless, these GBPs are selective in their binding. Using
both literature-based and affinity proteomics approaches, the
number of GBPs that interact with heparin/heparan sulfate was
estimated to be in the hundreds (Ori et al., 2011). Many hyal-
uronic acid-binding proteins and receptors are also known,
notably CD44 and TLR4 (Day and Prestwich, 2002).
Glycoproteomics
The highest resolution of the glycome would also allow an
assignment of individual glycan structures that are expressed
at each site on a particular glycoprotein. This assignment is obvi-
ously much easier for glycoproteins that express only a few
glycans compared to those that express hundreds. The higher
the number of glycosylation sites on a protein, the greater the
amount of material required for analysis as well as the greater
the complexity and time of analysis. Recently, site-specific
glycosylation of a-dystroglycan, a glycoprotein with >20 glyco-
sylation sites, has been characterized (Harrison et al., 2012; Stal-
naker et al., 2010). Newly developed ion-trap MS techniques to
fragment glycopeptides such that glycans can be fragmented
by CID, followed by ECD peptide fragmentation and identifica-
tion, have increased the possibility of assigning glycans to
particular amino acid sites in a mixture of glycopeptides (e.g.,
Halim et al., 2012). Nonetheless, the goal of assigning glycan
structures to specific sites on proteins in a complex mixture is
still formidable. A novel strategy to metabolically label glycopro-
tein glycans and GSLs of cultured cells using 15N-glutamine has
been developed. This methodology will allow using MS to study
the turnover of individual glycans on particular glycoproteins as
well as a detailed comparison of glycans in two populations of
cells that differ in some way, such as after differentiation, onco-
genic transformation, or exposure to a cytokine (Fang et al.,
2010; Orlando et al., 2009).
Glycogenes and Glycotranscriptomes
Among the initial steps to understand how the glycomes of hu-
man and mouse cells are regulated, the first requirement was
to produce a list of glycosylation-related enzymes and proteins.
The advent of the CaZY database (http://www.cazy.org), an up-
to-date, curated collection of enzymes/proteins from all sources
that act on carbohydrates, has allowed visualization of the
breadth of proteins that recognize glycans or are involved in their
metabolism (Nairn et al., 2008). This database, alongwith several
others, has been used to generate a ‘‘parts list’’ of transcripts en-
coding proteins known or hypothesized (because of sequence
identity or similarity) to bind, metabolize, or be directly involved
in complex glycan synthesis, breakdown, or transport (Figure 2).
The current list of transcripts involved in glycan recognition sug-
gests a total of around 200–210 transcripts in human andmouse.
The number of transcripts for putative GBPs, including GAG-
binding proteins and others that do not fit into the lectin rubric,
is obviously higher. Identification of the amounts of glycotran-
scripts expressed at any point in time by a particular cell type
and how those transcripts change during differentiation, disease
progression, or experimental perturbation reveal important clues
to understanding which glycans are expressed and their regula-
tion. The nature of the many agents that regulated glycosylation,
coupled with competition between biosynthetic enzymes, how-
ever, makes it very difficult to extrapolate from transcriptomeights reserved
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cans. Nevertheless, a recent study focused on the glycomics of
mouse embryonic stem cell differentiation to embryoid bodies
(EB) and extra-embryonic endoderm (EEE) in terms of both
glyco-transcript changes and glycan changes (Nairn et al.,
2012). The results suggested that in the vastmajority of the cases
studied between ESC and EB and between ESC and EEE differ-
entiation, changes in glycosyltransferase transcript levels were
consistent with the observed changes in glycan expression.
Glycobioinformatics
An overarching goal of bioinformatics focusing on glycomics,
also called glycobioinformatics, is to develop and provide tools
and algorithms that facilitate the study and identification of gly-
cans, their regulation, and function. This includes software
capable of interpreting analytical data to assign glycan struc-
tures, databases storing of glycan structures and metainforma-
tion, and algorithms linking these structural databases to protein
databases, such as UniProt. (http://www.uniprot.org). Although
analytical tools have not reached the degree of automation as
is common in proteomic analysis, they are becoming more
essential in the interpretation and display of experimental glyco-
mics structural data. Two widely used tools are GlycanBuilder
and GlycoWorkbench (Damerell et al., 2012). The most widely
used databases are listed in the Glycomics Portal (http://
glycomics.ccrc.uga.edu/GlycomicsPortal/) and allow not only
finding and retrieving information about glycan structures, but
also information about the interaction of these structures with
other macromolecules. For example, searching the CFG and
other databases containing glycan array binding data can assist
the identification of GBPs that recognize particular glycan struc-
tures or substructures (Kletter et al., 2013; McCarter et al., 2013;
Choletti et al., 2012).
Although progress has been made in developing and applying
such glycobioinformatic tools, many challenges remain. It ap-
pears timely to present several proposals for development of
bioinformatics tools in order to accelerate glycomics research.
(1) An international, open access/open source registry for glycan
structures must be developed. In order to facilitate communica-
tion between individuals, databases, and scientific literature,
an uncurated database that simply associates specific struc-
tures with a unique identifier (i.e., accession number) is required.
Such a ‘‘glycan namespace’’ will allow each structure, whether it
is confirmed or not, to be unambiguously specified by a single
identifier. These identifiers can then be used in the communica-
tion between tools and databases and will overcome the
diverse, incompatible glycan sequence formats currently in
use. In addition, a highly curated database containing vetted
glycan structures along with metadata (literature references,
species information, attachment of the glycan to other macro
molecules such as proteins, etc.) is required to facilitate the
annotation of laboratory data and provide conceptual links to
related biological entities and concepts. UniCarb (http://
unicarb-db.biomedicine.gu.seare) is making important initial
efforts toward such a curated database. Both of the databases
must be freely accessible and readable by both scientists and
computer programs. The curated database will be most useful
if it conforms to MIRAGE standards, as published in Molecular
and Cellular Proteomics (Kolarich et al., 2013). In addition storing
attachment information of glycan structures to glycoconjugatesChemistry & Biolwill provide an entry point that can be used by databases of other
research fields (e.g., proteomics). (2) Independent databases for
experimental glycomics data must also be developed based on
various methodologies used in glycomics, e.g., MS, NMR, LC-
MS, quantitative RT-PCR/deep sequencing. These databases,
which will be linked via the registries noted above with other
data sets, must not just contain the annotated data but also
the raw data and metadata about experimental procedures
used to generate and annotate the data. The information in these
databases must be accessible for researchers but also pre-
sented in machine-readable formats and interfaces that allow
interaction of the databases with annotation tools, e.g., via
web services. To facilitate this communication, at some point
there needs to be standardization and agreement on common
formats for glycan analysis data (i.e., MS annotation and glycan
array data). (3) Manuscripts published in journals and other pub-
lications must conform to MIRAGE standards, and clear data
deposition requirements, analogous to the requirement to sub-
mit coordinate files to the Protein Data Bank for three-dimen-
sional structure reports, must be established for publication. (4)
(Semi-)automatic annotation tools, similar to those in use for pro-
teomics, must be developed for interpreting and annotating tan-
dem MS and MSn data for glycan structure assignment. These
tools must allow sharing of data between users and assist with
deposition of data into common registries and databases.
To Glycoscience and Beyond
Glycoscience has made spectacular progress in the past few
years with the advent of new technologies for exploring glycan
structure and function along with insights into the genetic and
molecular aspects of glycan expression and regulation. The field
is challenged, however, by the complexity and dynamic nature
of the glycome and lack of understanding of how glycoconju-
gates are expressed topologically and temporally. Understand-
ing the functions of glycans and their higher order contributions
typically require physiological studies of organisms and identifi-
cation of altered pathways of anabolism and catabolism in
patients (Figure 7). Thus, combinations of studies in single cell
systems may fail to identify or even predict these higher order
functions. As for any type of biological system, the degree of un-
derstanding can be gauged by its predictive ability, and, on this
score, glycoscience is truly challenged. One Holy Grail for glyco-
mics researchers is to be able to predict the glycan structure(s) to
be found on any particular amino acid site on any glycoprotein of
interest; another is for functional glycomics researchers to pre-
dict the molecular interactions of a glycan with GBPs and
GRMs. At present, our state of knowledge is far from predictive
on any level, and we are limited to identifying potential sites of
glycosylation on proteins given their amino acid sequences.
Defining glycosylation sites and structures of glycans at specific
sites is still technically difficult and limited to laboratories with
advanced tools, especially considering all the types of amino
acid modifications that can occur (Figure 1). A further challenge
for glycomics is to understand the links between expression pat-
terns and levels of glycosyltransferases/glycosidases and their
localization, spatially and temporally, relative to particular glycan
structures aswell as the consequences of such expressions, and
that of GBPs, on biological activities. In spite of these challenges,
the future is growing brighter as our knowledge grows aboutogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 11
Figure 7. Relationship of Glycan Function to
Analytical Ease of Defining a Glycome
The higher order functions of glycans are typically
revealed in physiological studies of organisms,
and, to a lesser extent, perhaps in studies based
on isolated tissues and cells. Thus, mutations of
genes involved in specific glycosylation pathways
of anabolism or catabolism might have little
effect on cultured cells, but they are deleterious
to organismal development; increasing biological
complexity is denoted by the green arrow. Of
course, the analytical ease of defining the glycome
itself is simplified by considering free or released
glycans, compared to individual GSLs, such as a
glycoprotein, and becomes increasingly difficult
with larger biological complexity to the organism
itself, denoted by the blue arrow.
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through studies performed across many biological disciplines.
Technological advances in MS and other sequencing methods,
glycan synthesis, bioinformatics, and growing knowledge of bio-
logical roles of glycans in development, health, and disease,
notably the CDGs, provide great hope for the future of glyco-
mics. The possibility exists to finally tie the knot linking glycans
to nucleic acids, proteins, and lipids in the grand theory of every-
thing biological, assigning glycans their place as a pillar among
those macromolecules that are essential for life.ACKNOWLEDGMENTS
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